A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
NCT ID: NCT05559580
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
214 participants
INTERVENTIONAL
2022-12-13
2026-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to find out whether a medicine called Avenciguat (BI 685509) helps people with scleroderma who have symptoms due to lung fibrosis or vascular problems.
Participants are put into 2 groups by chance. One group takes Avenciguat (BI 685509) tablets 3 times a day and the other group takes placebo tablets 3 times a day. Placebo tablets look like BI 685509 tablets but do not contain any medicine. Participants take the tablets for at least 11 months. Afterwards, participants can continue to take the tablets until the last participant has completed the 11-months treatment period. This means that the time in the study and duration of treatment is different for each participant, depending on when they start the study. At the beginning of the study, participants visit the study site every 2 weeks. The time between the visits to the study site gets longer over the course of the study. After the 11-months treatment period, participants visit the study site every 3 months.
During the study, participants regularly do lung function tests. The results are compared between the 2 groups to see whether the treatment works. The participants also regularly fill in questionnaires about their scleroderma symptoms. The doctors regularly check participants' skin condition and general health and take note of any unwanted effects.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Avenciguat (BI 685509)
Avenciguat (BI 685509)
Avenciguat (BI 685509)
Avenciguat (BI 685509)
Placebo
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Avenciguat (BI 685509)
Avenciguat (BI 685509)
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female patients aged ≥18 years at time of consent (or above legal age, e.g. United Kingdom (UK) ≥16 years).
3. Patients must fulfill the 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria for Systemic sclerosis (SSc).
4. Patients must be diagnosed with limited or with diffuse cutaneous SSc as defined by LeRoy et al. (R17 0149). Patients diagnosed with limited cutaneous SSc may be included if they are anti Scl-70 antibody positive.
5. Diffuse cutaneous SSc disease onset (defined by first non-RP symptom) in patients with diffuse cutaneous SSc must be within 7 years of Visit 1. Limited cutaneous SSc onset must be within 2 years of Visit 1.
6. Evidence of active disease, defined as having at least one of the following:
* New onset of SSc within the last 2 years of Visit 1 OR
* New skin involvement or worsening of two new body areas within 6 months of Visit 1 (out of the possible 17 body areas defined by Modified Rodnan Skin Score (mRSS) assessment, documented in clinical files) OR
* New involvement or worsening of one new body area if either chest or abdomen within 6 months of Visit 1 OR
* Worsening of skin thickening (e.g. ≥2 mRSS points) within 6 months of Visit 1 OR
* ≥1 tendon friction rub
7. Elevated biomarkers on Visit 1 (screening) defined as at least one of the following:
* C-reactive protein (CRP) ≥6 mg/L (≥0.6 mg/dL), OR
* Erythrocyte sedimentation rate (ESR) ≥28 mm/h, OR
* Krebs von den Lungen 6 (KL-6) ≥1000 U/mL If none of the three criteria are met or respective test results should not be available, the patient can be entered if the modified Disease Activity Index (mDAI) is ≥ 2.5.
8. Evidence of significant vasculopathy, defined as:
* Active Digital ulcer (DU(s)) on Visit 1 OR
* Documented history of DU(s), OR
* Previous treatment of RP with prostacyclin analogues or ≥ 1 other medications, including calcium channel blockers, nitrates,, NO donors in any form, including topical; phosphodiesterase 5 (PDE5) inhibitors (e.g. sildenafil, tadalafil, vardenafil); nonspecific PDE5 inhibitors (theophylline, dipyridamole) OR
* RP with elevated CRP ≥6 mg/L
Exclusion Criteria
2. Pulmonary disease with FVC \<50% of predicted. at screening.
3. Other autoimmune connective tissue diseases, except for fibromyalgia, scleroderma-associated myopathy and secondary Sjogren syndrome.
4. Diffusing capacity for carbon monoxide (DLCO) (haemoglobin corrected) \<40% of predicted at screening.
5. Any history of scleroderma renal crisis within the last 6 months.
6. Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 (Chronic Kidney Disease Epidemiology (CKD-EPI) formula) or on dialysis at screening.
7. Cirrhosis of any Child-Pugh class (A, B or C).
8. Cholestasis at present, or Alkaline phosphatase (ALP) \> 4 x Upper limit of normal (ULN), or ALP \> 2 x ULN and Gamma-glutamyl transferase (GGT) \> 3 x ULN at Screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Mayo Clinic
Scottsdale, Arizona, United States
Medvin Clinical Research-Covina-67001
Covina, California, United States
Southern California Scleroderma and Rheumatology Center
Inglewood, California, United States
University of California Los Angeles
Los Angeles, California, United States
Medvin Clinical Research-Whittier-69033
Whittier, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
University of Florida
Gainesville, Florida, United States
Mayo Clinic - Florida
Jacksonville, Florida, United States
Iris Research and Development
Plantation, Florida, United States
The Emory Clinic
Atlanta, Georgia, United States
Augusta University
Augusta, Georgia, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Tufts Medical Center
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan Health System
Ann Arbor, Michigan, United States
Mayo Clinic, Rochester
Rochester, Minnesota, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Centro de Investigaciones Metabolicas (CINME)-C.A.B.A-61553
C.a.b.a, , Argentina
Hospital Britanico de Buenos Aires
CABA, , Argentina
STAT Research
CABA, , Argentina
Instituto de Investigación Clínica TyT
CABA, , Argentina
Psoriahue Medicina Interdisciplinaria S.R.L
CABA, , Argentina
Hospital Italiano de La Plata
La Plata, , Argentina
Centro de Investigaciones Medicas Mar del Plata
Mar del Plata, , Argentina
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
Medical University of Graz State Hospital - University Hospital Graz
Graz, , Austria
Ordensklinikum Linz GmbH
Linz, , Austria
ULB Hopital Erasme
Brussels, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
UZ Leuven
Leuven, , Belgium
Centre Hospitalier Universitaire de Liège
Liège, , Belgium
Edumed - Educacao e Saude SA
Curitiba, , Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, , Brazil
CEMEC - Centro Multidisciplinar de Estudos Clínicos
São Bernardo do Campo, , Brazil
Hospital do RIM - UNIFESP
São Paulo, , Brazil
St. Paul's Hospital (Vancouver)
Vancouver, British Columbia, Canada
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Mount Sinai Hospital-Toronto-18157
Toronto, Ontario, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
Centro Internacional de Estudios Clínicos (CIEC)
Comuna de Recoleta, , Chile
Clínica Dermacross S.A.
Vitacura, , Chile
Peking Union Medical College Hospital
Beijing, , China
Peking University Third Hospital
Beijing, , China
The First Affiliated Hospital Of Bengbu Medical College
Bengbu, , China
The First Hospital of Jilin University
Changchun, , China
West China Hospital of Sichuan University
Chengdu, , China
Guangdong Provincial People's Hospital
Guangzhou, , China
The third affiliated hospital of Sun Yat-Sen University
Guangzhou, , China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, , China
Nanjing Drum Tower Hospital
Nanjing, , China
The First Affiliated Hospital of Ningbo University
Ningbo, , China
Huashan Hospital, Fudan University
Shanghai, , China
The First Affiliated Hospital of Soochow University
Suzhou, , China
Tianjin Medical University General Hospital
Tianjin, , China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, , China
Wuhan Union Hospital
Wuhan, , China
Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T
Wuhan, , China
Institute of Rheumathology Prague
Prague, , Czechia
Medical Plus s.r.o., Rheumatology Outpatient Clinic
Uherské Hradiště, , Czechia
Aarhus University Hospital
Aarhus N, , Denmark
Kuopio University Hospital
Kuopio, , Finland
TYKS
Turku, , Finland
HOP Annecy-Genevois
Epagny Metz-Tessy, , France
HOP Hôtel-Dieu
Nantes, , France
Hôpital Cochin
Paris, , France
HOP Pontchaillou
Rennes, , France
HOP Civil
Strasbourg, , France
HOP Rangueil
Toulouse, , France
HOP Brabois
Vandœuvre-lès-Nancy, , France
Charite Universitätsmedizin Berlin KöR
Berlin, , Germany
Universitätsklinikum Köln (AöR)
Cologne, , Germany
Universitätsklinikum Erlangen
Erlangen, , Germany
Universitätsklinikum Heidelberg
Heidelberg, , Germany
Klinikum der Universität München AÖR
München, , Germany
Westfälische Wilhelms-Universität Münster
Münster, , Germany
General Hospital of Athens "Laiko"
Athens, , Greece
General Hospital of Athens "Laiko"
Athens, , Greece
St John's Medical College
Bangalore, , India
Post Graduate Institute of Medical Education and Research
Chandigarh, , India
Sree Sudheendra Medical Mission
Kochi, , India
Post Graduate Institute of Medical Education and Research
Kolkata, , India
Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute
Maharashtra, , India
Chopda Medicare and Research Centre Pvt Ltd
Maharashtra, , India
All India Institute of Medical Sciences
New Delhi, , India
Grant Medical Foundation, Ruby Hall Clinic
Pune, , India
Krishna Institute of Medical Sciences
Secunderabad, , India
Rambam Medical Center
Haifa, , Israel
Bnai Zion Medical Center, Haifa
Haifa, , Israel
Meir Medical Center
Kfar Saba, , Israel
Western Galilee Hospital
Nahariya, , Israel
The Chaim Sheba Medical Center Tel HaShomer
Ramat Gan, , Israel
Ospedali Riuniti di Ancona
Ancona, , Italy
A.O. Spedali Civili di Brescia
Brescia, , Italy
Azienda Ospedaliero Universitaria Careggi
Florence, , Italy
Azienda Ospedaliera San Martino
Genova, , Italy
Istituto Ortopedico G.Pini
Milan, , Italy
Ospedale San Raffaele S.r.l.
Milan, , Italy
Azienda Ospedaliera Policlinico di Modena
Modena, , Italy
Fondazione Policlinico Universitario Campus Bio-medico
Roma, , Italy
AOU Policlinico Umberto I
Roma, , Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, , Italy
Japan Community Healthcare Organization Chukyo Hospital
Aichi, Nagoya, , Japan
Hospital of the University of Occupational and Environmental Health
Fukuoka, Kitakyushu, , Japan
Hokkaido University Hospital
Hokkaido, Sapporo, , Japan
Kanazawa University Hospital
Ishikawa, Kanazawa, , Japan
Kyoto University Hospital
Kyoto, Kyoto, , Japan
The University of Osaka Hospital
Osaka, Suita, , Japan
Nippon Medical School Hospital
Tokyo, Bunkyo-ku, , Japan
Wakayama Medical University Hospital
Wakayama, Wakayama, , Japan
University of Malaya Medical Centre
Kuala Lumpur, , Malaysia
Hospital Selayang
Kuala Selangor, , Malaysia
Investigacion y Biomedicina de Chihuahua S.C.
Chihuahua City, , Mexico
Centro Integral en Reumatologia, SA. de CV.
Guadalajara, , Mexico
Medical Care & Research SA de CV
Mérida, , Mexico
Oaxaca Site Management Organization, S.C.
Oaxaca City, , Mexico
Leids Universitair Medisch Centrum (LUMC)
Leiden, , Netherlands
Radboud Universitair Medisch Centrum
Nijmegen, , Netherlands
Waikato Hospital
Hamilton, , New Zealand
Oslo Universitetssykehus HF, Rikshospitalet
Oslo, , Norway
Manila Doctors Hospital
Manila, , Philippines
St. Luke's Medical Center-Quezon-59457
Quezon City, , Philippines
Malopolska Clinical Research
Krakow, , Poland
Medical Center Hetmanska
Poznan, , Poland
National Medical Institute MSWiA
Warsaw, , Poland
Prof Eleonora Reicher Memorial Institute of Rheumatology
Warsaw, , Poland
Military Medical Institute- National Research Institute
Warsaw, , Poland
ULS de Almada -Seixal, E. P. E. - Hospital Garcia de Orta
Almada, , Portugal
Bacau County Hospital
Bacau, , Romania
C.M.D.T.A. NEOMED, Brasov
Brasov, , Romania
Dr. Ion Cantacuzino Clinical Hospital
Bucharest, , Romania
S.C. Policlinica CCBR S.R.L.
Bucharest, , Romania
St. Mary's Clinical Hospital
Bucharest, , Romania
Cluj Napoca Clinical County Hospital
Cluj-Napoca, , Romania
Aqua Clinic (AquaMed Consulting SRL- juridic)
Constanța, , Romania
SC Medaudio Optica SRL
Râmnicu Vâlcea, , Romania
Singapore General Hospital
Singapore, , Singapore
Tan Tock Seng Hospital
Singapore, , Singapore
Seoul National University Hospital
Seoul, , South Korea
Soonchunhyang University Hospital Seoul
Seoul, , South Korea
Hanyang University Medical Center
Seoul, , South Korea
Hospital Santa Creu i Sant Pau
Barcelona, , Spain
Hospital Universitari Vall D Hebron
Barcelona, , Spain
Hospital Universitario Ramon Y Cajal
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Clínico de Santiago
Santiago de Compostela, , Spain
Hospital Dr. Peset
Valencia, , Spain
Clinical Rheumatology Research Center Sahlgrenska
Gothenburg, , Sweden
Kantonsspital St.Gallen
Sankt Gallen, , Switzerland
University Hospital Zurich
Zurich, , Switzerland
National Taiwan University Hospital
Taipei, , Taiwan
Maharaj Nakom Chiangmai Hospital
Chiang Mai, , Thailand
Songklanagarind Hospital
Hat Yai, , Thailand
Srinagarind Hospital
Muang, , Thailand
Ramathibodi Hospital
Ratchathewi, , Thailand
Akdeniz Universitesi Tip Fakultesi -ANTALYA-33606
Antalya, , Turkey (Türkiye)
Firat University Hospital
Elâzığ, , Turkey (Türkiye)
Chapel Allerton Hospital
Leeds, , United Kingdom
Aintree University Hospital
Liverpool, , United Kingdom
Royal Free Hospital
London, , United Kingdom
Salford Royal
Salford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kaufman J, Nabozny G, Tran-Manh C, Liebel C, Zhou X, Daley LA, Wang CT, Ebenezer DL, Delic D, Wohnhaas CT, Trinh-Minh T, Distler JHW. Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis. Rheumatology (Oxford). 2025 Aug 1;64(8):4738-4743. doi: 10.1093/rheumatology/keaf109.
Khanna D, de Vries-Bouwstra J, Hoffmann-Vold AM, Kuwana M, Low AHL, Proudman S, Flack M, Kukreja A, Fagan N, Distler O. A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE study. J Scleroderma Relat Disord. 2024 Nov 7:23971983241291923. doi: 10.1177/23971983241291923. Online ahead of print.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-500332-11-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
1366-0031
Identifier Type: -
Identifier Source: org_study_id